None
Quote | Juno Therapeutics Inc. (NASDAQ:JUNO)
Last: | $ |
---|---|
Change Percent: | 0.02% |
Open: | $86.62 |
Close: | $86.60 |
High: | $86.63 |
Low: | $86.56 |
Volume: | 5,355,348 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Juno Therapeutics Inc. (NASDAQ:JUNO)
Summary LAVA is able to form a highly profitable partnership with Seagen to develop LAVA-1223 for various solid tumors. The company's Gammabody platform holds strong promises as a delivery vehicle for a differentiated type of cellular therapy. There is an upcoming data release...
June 16 (UPI) -- The 100-plus carat Juno diamond was auctioned Thursday in New York by Sotheby's, bringing in over $12.9 million. The Earth Star, an orange-brown diamond of 111.59 carats, was expected to bring as much as $2.5 million. The Juno diamond is a 101.41 carat pear-shap...
Message Board Posts | Juno Therapeutics Inc. (NASDAQ:JUNO)
Subject | By | Source | When |
---|---|---|---|
Still holding up. Very good sign! | JJSimmons | investorshub | 01/25/2018 3:31:49 PM |
Love how it held up. Normally these | JJSimmons | investorshub | 01/24/2018 9:56:40 PM |
No kidding. I bought back in September | JJSimmons | investorshub | 01/23/2018 1:14:05 PM |
WOO HOO!!!! THANK YOU $JUNO!!! | SirCharChar | investorshub | 01/22/2018 2:57:50 PM |
Announced today - 9b / $87 | Awl416 | investorshub | 01/22/2018 1:16:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Juno Therapeutics Inc. Company Name:
JUNO Stock Symbol:
NASDAQ Market:
Juno Therapeutics Inc. Website:
June 16 (UPI) -- The 100-plus carat Juno diamond was auctioned Thursday in New York by Sotheby's, bringing in over $12.9 million. The Earth Star, an orange-brown diamond of 111.59 carats, was expected to bring as much as $2.5 million. The Juno diamond is a 101.41 carat pear-shap...
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...